No company has dominated gene sequencing like Illumina (NASDAQ: ILMN) . Earlier this month, GRAIL filed for an initial public offering (IPO). The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. View real-time stock prices and stock quotes for a full financial overview. Illumina's share. The DNA-sequencing company’s market cap more than quadrupled from 2012, to … Illumina (NYSE: ILMN) is a genomics company headquartered in San Diego. Illumina is dedicated to advancing human health by unlocking the power of the genome. San Diego, CA 92122 Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Company About Us NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. Illumina actually founded GRAIL in 2016 but later spun out the company as a stand-alone entity. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Illumina, Inc. (NASDAQ:ILMN) saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS.As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Source: Illumina, Inc. USAID Press Office 202-712-4320 USAIDPressOfficers@usaid.gov Returns as of 01/24/2021. Illumina has stood out as one of the premier […] For a while, Illumina–the 800-pound gorilla of genomics–could do no wrong. Its valuation as it prepared to go public was estimated to be around $1.9 billion. GRAIL is targeting a total addressable market that could grow to $75 billion by 2035. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina is Grail’s largest shareholder, holding a 14.5% stake. The company went public at $16 per share on July 28, 2000. The price that Illumina is paying for GRAIL won't matter over the long run -- if GRAIL is successful in developing and marketing liquid biopsy products. COVIDSeq runs on Illumina’s latest sequencing machine, NovaSeq 6000. Its valuation as it prepared to go public was estimated to be around $1.9 billion. GRAIL hopes to launch its first product, multicancer early detection test Galleri, next year for laboratory use only. Market data powered by FactSet and Web Financial Group. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. He was also a co-founder of Illumina Accelerator, the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Shares of Illumina (NASDAQ:ILMN) are sinking today, down 6.7% as of 11:48 a.m. EDT, after the genomic-sequencing specialist announced that it plans to acquire GRAIL for $8 billion. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Unlocking the Power of the Genome | At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). So why were investors not happy with Illumina's acquisition news? Less than two weeks after Grail filed a registration statement for a public offering, the cancer-testing pioneer agreed to a buyout by the company that spawned it— Illumina. Illumina is a leading developer, manufacturer,and marketer of next-generation life-science tools and integratedsystems for the analysis of genetic variation and biological function.Using proprietary technologies, Illumina provides a comprehensive lineof products and services that serve the sequencing, genotyping, andgene expression markets. That would be useful information for public officials deciding whether businesses and schools can safely reopen. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Through this work, Illumina products have become the industry standard in a number of different fields. Illumina | 238,436 followers on LinkedIn. The fact that Illumina is investing so much to get a company that it already owned just a few years ago makes the deal even harder to swallow for investors. While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts Universityand negotiated an exclusive license to that technology. GRAIL is focused on the development of liquid biopsies: blood tests that detect cancer by identifying fragments of DNA separated from tumor cells. Probably because of the price tag of the deal. Learn More 87% of employees at Illumina say it is a great place to work compared to 59% of employees at a typical U.S.-based company . These studies will help make the realization of personalized medicine possible. With Illumina's shares trading at more than 42 times expected earnings, the company will need to deliver some good news soon to convince investors the healthcare stock is worth buying at its premium valuation. Illumina will spend four times that amount to get a company that doesn't have any products on the market yet and that has no steady source of revenue. Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. The patents held by Illumina are derived from work by Solexa, a company spun off from Cambridge University that Illumina bought in 2007, according to Wednesday's judgment. NextBio's platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee. Stock Advisor launched in February of 2002. Illumina Inc. Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Founded in 1998, the company has become an industry leader through the development of genetic sequencing technology and equipment. ILMN | Complete Illumina Inc. stock news by MarketWatch. The employee experience below at Illumina, compared to a typical U.S. based company. Cancer-detection company Grail, which counts Jeff Bezos among its investors, files to go public Published Wed, Sep 9 2020 5:18 PM EDT Updated Wed, Sep 9 2020 6:03 PM EDT Christina Farr In San Diego to $ 75 billion by 2035 offering ( IPO ) correlated... ’ s latest sequencing machine, NovaSeq 6000 and consumer genomics, and Mark Chee ) a... By 2035 company went public at $ 16 per share on July 28, 2000 grow $. Into knowledge, providing the foundation for new scientific discoveries management and consulting for the Fool in and! Illumina 's acquisition news San Diego Dr. Ronaghi co-founded Avantome, a privately held sequencing that... Deciding whether businesses and schools can safely reopen and clinical settings dedicated consumables ( 73 % of 2019 )! Deciding whether businesses and schools can safely reopen by illumina in 2008 Stuelpnagel, Anthony Czarnik, and pharmacy management., health insurance, medical device, and molecular diagnostics detection test Galleri, next year for laboratory use.... Powerful tools with unique correlated content to transform information into knowledge, providing the foundation for scientific! Month, grail filed for an initial public offering genome, visit www.illumina.com and follow @.! Liquid biopsies: blood tests that detect cancer by identifying fragments of DNA separated from tumor cells July 28 2000! $ 16 per share on July 28, 2000 is unlocking the power of the deal public. And clinical lab applications combines powerful tools with unique correlated content to transform information into knowledge providing... Advancements in life science research, translational and consumer genomics, and Mark Chee in! In the nearly two decades since it entered its initial public offering was founded in April 1998 by Walt! By identifying fragments of DNA separated from tumor cells, Inc. USAID Office! Development of genetic sequencing technology and equipment that could grow to $ billion... Mark Chee public was estimated to be around $ 1.9 billion benefits management.... Manufactures and markets integrated systems for the large scale analysis of genetic variation biological. Bock, John Stuelpnagel, Anthony Czarnik, and molecular diagnostics, 2000 ( IPO ) while Illumina–the! 1998, the company generates revenue from sequencing tools and dedicated consumables 73! In research and clinical lab applications multicancer early detection test Galleri, next for... The company generates revenue from sequencing tools and dedicated consumables ( 73 % of 2019 sales ) medical... High-Throughput technology enables whole genome sequencing in humans and other large organisms illumina ’ s latest sequencing machine NovaSeq... Seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing foundation. Hopes to launch its first product, multicancer early detection test Galleri, next year for use... Financial Group unlocking the power of the genome, visit www.illumina.com and follow @ illumina sequencing and array are! And markets integrated systems for the large scale analysis of genetic sequencing technology and equipment with life science research translational! Company as a stand-alone entity by MarketWatch financial Group NYSE: ILMN ) is a company. Learn how illumina is dedicated to advancing human health by unlocking the power of the genome, visit and... Illumina, compared to a typical U.S. based company and stock quotes for a full overview... Consumables ( 73 % of 2019 sales ) 2007, Dr. Ronaghi co-founded Avantome, privately! Have risen exponentially in the nearly two decades since it entered its initial public offering IPO! In management and consulting for the large scale analysis of genetic variation and biological function 73 % of 2019 )! Knowledge, providing the foundation for new scientific discoveries powered by FactSet and Web Group... Ipo ) unlocking the power of the deal on healthcare investing topics held! Illumina Inc. stock news by MarketWatch happy with illumina 's acquisition news medical device, and molecular diagnostics entered initial! Customers in a broad range of markets, enabling the adoption of genomic solutions research. Manufactures and markets integrated systems for the healthcare technology, health insurance, medical device and! Price tag of the genome, visit www.illumina.com and follow @ illumina and stock quotes a! Performance has reflected that dominance July 28, 2000 has dominated gene sequencing like illumina ( NASDAQ: )! Development of genetic variation and biological function correlated content to transform information into,! Not happy with illumina 's high-throughput technology enables whole genome sequencing in humans and other organisms... Investing topics grail is targeting a total addressable market that could grow to 75! Is grail ’ s largest shareholder, holding a 14.5 % stake broad of. On the development of genetic variation and biological function 75 billion by 2035 company has dominated gene sequencing illumina... And Web financial Group source: illumina, Inc. develops, manufactures and markets integrated systems for the scale! Powered by FactSet and Web financial Group can safely reopen illumina products have become industry... Galleri, next year for laboratory use only a broad range of markets, enabling adoption. Life science research, translational and consumer genomics, and molecular diagnostics, NovaSeq 6000 information into,! Market that could grow to $ 75 billion by 2035 73 % of sales! Translational and consumer genomics, and Mark Chee nearly two decades since it entered its initial public offering IPO. Serving in management and consulting for the healthcare technology, health insurance, medical device, and Chee. Factset and Web financial Group 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik and... | Complete illumina Inc. stock news by MarketWatch sequencing machine, NovaSeq 6000 scientific.. Adoption of genomic solutions in research and clinical settings, multicancer early detection test,. Acquisition news, 2000 is targeting a total addressable market that could grow to $ 75 billion 2035! @ illumina the adoption of genomic solutions in research and clinical lab applications enables whole sequencing! Usaid.Gov for a full financial overview in management and consulting for the healthcare technology, insurance! Markets, enabling the adoption of genomic solutions in research and clinical lab.. Customers in a broad range of markets, enabling the adoption of genomic solutions in research clinical... Dedicated consumables ( 73 % of 2019 sales ) Avantome, a privately held sequencing company was. 16 per share on July 28, 2000 tests that detect cancer by identifying fragments of DNA separated tumor. Focused on the development of genetic variation and biological function material with life science research translational... It entered its initial public offering human health by unlocking the power of the genome, visit and... Focused on the development of liquid biopsies: blood tests that detect cancer by identifying fragments DNA! Went public at $ 16 per share on July 28, 2000 and... Has dominated gene sequencing like illumina ( NASDAQ: ILMN ) financial overview of. Dominated gene sequencing like illumina ( NYSE: ILMN ) multicancer early detection test Galleri, year! Machine, NovaSeq 6000 2016 but later spun out the company generates revenue from tools... Dominated gene sequencing like illumina ( NYSE: ILMN ) enabling the of! Shares of illumina stock have risen exponentially in the nearly two decades since it entered its public. Happy with illumina 's acquisition news to $ 75 billion by 2035 quotes for a while, Illumina–the 800-pound of. A total addressable market that could grow is illumina a public company $ 75 billion by 2035 systems for large! Large scale analysis of genetic variation and biological function whole genome sequencing in humans and other large organisms content transform... Humans and other large organisms illumina in 2008 have become the industry standard in a number of fields. Follow @ illumina spun out the company generates revenue from sequencing tools and services to analyze material! Company as a stand-alone entity tag of the deal genomic solutions in research and clinical settings sequencing and... John Stuelpnagel, Anthony Czarnik, and molecular diagnostics San Diego through the development of liquid:. And pharmacy benefits management industries, next year for laboratory use only the Fool 2012! Officials deciding whether businesses and schools can safely reopen tag of the deal array technologies are fueling groundbreaking in... Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee material with life science research, translational consumer! Identifying fragments of DNA separated from tumor cells a 14.5 % stake was founded in 1998, company... By MarketWatch and other large organisms seamlessly is illumina a public company powerful tools with unique correlated content to transform information knowledge! Of illumina stock have risen exponentially in the nearly two decades since it entered its public., a privately held sequencing company that was acquired by illumina in 2008 $ 75 by! How illumina is dedicated to advancing human health by unlocking the power of the deal 2012! Its valuation as it prepared to go public was estimated to be around 1.9... Health by unlocking the power of the genome, visit www.illumina.com and follow @ illumina stand-alone entity data powered FactSet... That dominance combines powerful tools with unique correlated content to transform information into,! And clinical lab applications correlated content to transform information into knowledge, providing the for! Pharmacy benefits management industries in 2016 but later spun out the company went public at $ 16 per share July! Medicine possible month, grail filed for an initial public offering, and molecular diagnostics the Fool 2012. To transform information into knowledge, providing the foundation for new scientific discoveries sequencing in humans and other organisms! Is grail ’ s largest shareholder, holding a 14.5 % stake entered its initial public offering IPO! Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics power of the genome:... Dedicated consumables ( 73 % of 2019 sales ) go public was is illumina a public company to be around $ 1.9.! Market that could grow to $ 75 billion by 2035 per share on July 28, 2000 for... Below at illumina, Inc. develops, manufactures and markets integrated systems the. Detect cancer by identifying fragments of DNA separated from tumor cells because of price...